Posted by Michael Wonder on 10 Aug 2022
Cure Rare Disease receives FDA approval to administer first in human CRISPR therapeutic
10 August 2022 - Cure Rare Disease announces the approval from the US FDA to administer its very first therapeutic.
The drug, named CRD-TMH-001, treats muscle promoter and exon 1 mutations on the dystrophin gene.
With the IND approval process complete, the FDA has given the go-ahead, and dosing of the drug will occur imminently at UMass Chan Medical School.
